Sawyer & Company Inc Sells 775 Shares of Johnson & Johnson (NYSE:JNJ)

Sawyer & Company Inc cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,137 shares of the company’s stock after selling 775 shares during the period. Johnson & Johnson comprises approximately 2.5% of Sawyer & Company Inc’s portfolio, making the stock its 8th largest position. Sawyer & Company Inc’s holdings in Johnson & Johnson were worth $3,780,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Zions Bancorporation N.A. increased its stake in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock valued at $2,810,000 after acquiring an additional 73 shares in the last quarter. Cambridge Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.3% in the 4th quarter. Cambridge Advisors Inc. now owns 22,436 shares of the company’s stock valued at $2,895,000 after acquiring an additional 78 shares in the last quarter. Vishria Bird Financial Group LLC increased its stake in shares of Johnson & Johnson by 3.0% in the 2nd quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock valued at $381,000 after acquiring an additional 80 shares in the last quarter. Burt Wealth Advisors increased its stake in shares of Johnson & Johnson by 0.6% in the 4th quarter. Burt Wealth Advisors now owns 12,898 shares of the company’s stock valued at $1,665,000 after acquiring an additional 82 shares in the last quarter. Finally, Timber Creek Capital Management LLC increased its stake in shares of Johnson & Johnson by 8.7% in the 4th quarter. Timber Creek Capital Management LLC now owns 1,035 shares of the company’s stock valued at $133,000 after acquiring an additional 83 shares in the last quarter. Institutional investors and hedge funds own 66.78% of the company’s stock.

JNJ stock traded up $0.78 during midday trading on Friday, reaching $131.07. 6,573,218 shares of the company’s stock traded hands, compared to its average volume of 7,301,963. The firm has a market capitalization of $343.67 billion, a P/E ratio of 16.02, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69. The firm has a fifty day simple moving average of $136.70. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.13 and a current ratio of 1.33. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. Johnson & Johnson’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.10 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is 46.45%.

A number of brokerages have commented on JNJ. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 17th. BMO Capital Markets boosted their price target on shares of Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Bank of America restated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Finally, Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research note on Tuesday, May 28th. They set a “buy” rating for the company. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Buy” and an average target price of $148.56.

In other news, Director Marillyn A. Hewson acquired 3,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, with a total value of $419,040.00. Following the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at $419,040. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.23% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Marijuana Stocks

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.